Allison Grimes, MD Pediatric Hematology/Oncology, Adolescent and Young Adults
Gail Tomlinson, MD, PhD Pediatric Hematology Oncology, Cancer Genetics & High-Risk Screening
Debra Kent, DNP, MSN, APRN-PC, RN Pediatric Nurse Practitioner, Oncology Survivorship
Robert Christopher Gilson, MD, FAAD Dermatology, Pediatric Dermatology
APEC1621B, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with relapsed pediatric solid tumors harboring FGFR1/2/3/4 alteration
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Shafqat Shah, M.D. Pediatric Hematology/Oncology, Pediatrics
Anne–Marie Langevin, MD Pediatric Hematology/Oncology, Pediatrics
APEC1621G, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in patients with tumors harboring BRAF V600 mutations
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.